Jon Sakoda
CIK 1589961 · last filed 2018-06-28
Jon Sakoda is a corporate insider who has filed 15 SEC Form 4 insider transactions across 6 companies since 2015. The most recent filing shows the insider bought $404.1K of AVEO on Jun 28, 2018. Across all open-market trades the lifetime net is +$35.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $9.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 1,759,659 | $15.00 | $26.39M | $6.17M | 6 | 2018-06-28 |
| ARDX | 10%+ Owner | 3,082,186 | $3.00 | $9.25M | $23.33M | 3 | 2018-05-30 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| OPOWER, INC. (OPWR) Delisted | Director | 0 | — | — | $0 | 2 | 2015-06-10 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-28 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +192,425 | $404.1K | EDGAR |
| 2018-05-30 | ARDX | Grant (A) | +833,333 | $3.33M | EDGAR |
| 2018-05-30 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +275 | $591 | EDGAR |
| 2018-05-21 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +236,479 | $503.4K | EDGAR |
| 2018-05-10 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +70,873 | $151.3K | EDGAR |
| 2018-04-10 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +920,976 | $2.12M | EDGAR |
| 2018-03-13 | — | U | −10,882,574 | $0 | |
| 2018-02-27 | Oruka Therapeutics, Inc. (ABIO) Delisted | Sell (S) | −1,460,209 | -$731.3K | EDGAR |
| 2018-02-22 | Cascadian Therapeutics, Inc. (CASC) Delisted | Conv (C) | +1,818,000 | $6.00M | EDGAR |
| 2017-03-29 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +6,000,000 | $3.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.